Drugs With Semaglutide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Two large medical studies from Denmark presented in December 2024 provide more evidence of a link between Ozempic and an eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), finding that people who used Ozempic have more than a two-times increased risk of developing this serious eye side effect, which can cause vision loss and blindness.
These two Danish medical studies serve to confirm what was first reported in a July 2024 medical journal article, that Wegovy, Rybelsus, and Ozempic are linked to eye problems because semaglutide, which is the active ingredient for each of these three drugs, is associated with NAION.
Eye-related side effects of Ozempic, Wegovy, and Rybelsus with possible vision loss is a drug safety issue for these semaglutide-containing medications from Novo Nordisk that is generally unknown to many.
Here is what you need to know:
- Ozempic, Wegovy, and Rybelsus are drugs with semaglutide as their active ingredient.
- Semaglutide has been linked to nonarteritic anterior ischemic optic neuropathy (NAION).
- NAION is sometimes referred to as an “eye stroke,” and it occurs when there is a lack of sufficient blood flow to the optic nerve.
- NAION typically causes sudden vision loss and, in severe cases, can lead to blindness.
- There are currently no proven treatments for NAION.
The current drug labels for Ozempic, Wegovy, and Rybelsus do not warn about eye-related side effects, such as possible vision loss.
We are looking into possible drug injury lawsuits for patients who developed eye-related side effects of Ozempic, Wegovy, and Rybelsus from Novo Nordisk.
Drug injury lawsuits involving Ozempic, Wegovy, and Rybelsus for patients with vision loss due to nonarteritic anterior ischemic optic neuropathy (NAION) would be filed against Novo Nordisk for its failure to warn about any eye problems such as vision loss.
And because there are no warnings in the current drug labels about an increased risk of eye-related side effects for Ozempic, Wegovy, and Rybelsus, those drug injury cases would not be filed against patients’ doctors.
Free Case Evaluation for Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus
We encourage you to submit an Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Ozempic, Wegovy, or Rybelsus drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Article About Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
Semaglutide NAION Lawsuits in 2026 for Wegovy, Rybelsus, Ozempic Vision Loss
Semaglutide NAION lawsuits in 2026 are based on the failure to warn about this serious eye side effect. These court cases seek legal compensation for patients diagnosed with NAION vision loss or blindness.
In more detail, lawsuits for Wegovy, Rybelsus, and Ozempic vision loss cases involving semaglutide-associated nonarteritic anterior ischemic optic neuropathy (NAION) are filed against Novo Nordisk, the pharmaceutical company responsible for those three semaglutide-containing GLP-1 drugs. This is because, at present, there is no warning about semaglutide-associated NAION in the current drug labels for Ozempic, Rybelsus, and Wegovy.
Some new important evidence for these semaglutide NAION lawsuits involving Ozempic, Rybelsus, and Wegovy is found in this medical journal article published in May 2026 by PLOS Medicine, “Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies“.
To read more of this article, click below:
From the Abstract for this recent PLOS Medicine medical journal article relevant to Wegovy, Rybelsus, and Ozempic NAION vision loss cases:
Conclusions: Our findings suggest a possible association between semaglutide use and an increased risk of NAION in patients with [type 2 diabetes (T2DM)]. Although the absolute risk is low, clinicians should be aware of this potential adverse event, particularly in individuals at increased baseline risk for optic neuropathies. While these findings support current recommendations to discontinue semaglutide in patients diagnosed with NAION, the certainty of the available evidence is low, underscoring the need for further high-quality studies to clarify this association.
However, as we pointed out above, the current drug labels for Ozempic, Wegovy, and Rybelsus do not have any warning about semaglutide-associated NAION vision loss or blindness as a possible side effect.
As seen by this list of earlier Drug Injury Law articles, our law firm is very familiar with the semaglutide-associated NAION side effects of Ozempic, Wegovy, and Rybelsus:
- Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
- Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
In addition, our law firm has experience handling semaglutide NAION lawsuits involving Wegovy, Rybelsus, and Ozempic vision loss or blindness cases for patients.
Patients diagnosed with NAION-related vision loss or blindness can submit an Ozempic/Wegovy/Rybelsus Vision Loss Case Evaluation Form online. Or, if you prefer, call 910-256-2971 to talk with drug injury lawyer Tom Lamb about semaglutide NAION lawsuits.
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Ozempic, Wegovy, and Rybelsus:
- NAION Linked To Zepbound Mounjaro, Ozempic, Wegovy: 2026 News Update
- Ozempic and Wegovy NAION Study 2026 Report: Two New Findings
- Ozempic-NAION Warnings Should Be In January 2026 Drug Label For New Pill Version
- Ozempic NAION Risk 200% Higher Than Some Other Diabetes Drugs
- Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
- Ozempic Vision Loss Claims Compensation Payments Made in 2025
- Ozempic NAION Rate Higher in Recent 2025 Medical Study
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- Link Between Ozempic and NAION Also Involves the Eye Disorder AION
- Ozempic Blindness Legal Cases Filed Against Novo Nordisk in April 2025
- Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
- Ozempic Eye Problems Caused by Semaglutide-Related NAION
- Ozempic Linked to Vision Loss With Increased Risk of NAION Side Effect
- Ozempic Side Effects Include Eye Problems With Possible Vision Loss
Other articles about Ozempic, Wegovy, and Rybelsus by attorney Tom Lamb on the Side Effects Blog:
- Rybelsus Pancreatitis Warnings and Rybelsus Drug Injury Lawsuits
- A Rybelsus Blood Clots DVT Case
- Semaglutide-Related Blood Clots Cases: Ozempic, Wegovy, and Rybelsus
- Deep Vein Thrombosis When Using Wegovy, Rybelsus, or Ozempic
- Wegovy / Rybelsus / Ozempic Deep Vein Thrombosis Side Effects
- Symptoms and Diagnosis of Weight-Loss Drugs Gastroparesis Side Effects for Ozempic, Rybelsus, Wegovy, and Trulicity
- Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study
- Ozempic Intestinal Blockage and Obstruction Cases Increasing
- Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
- Ozempic-Related Gastroparesis, Stomach Paralysis, Intestinal Blockages